Novel therapies for inflammatory bowel disease

Recent advances in our understanding of the basic processes that contribute to inflammatory bowel disease have led to the identification of new target s for therapy Novel therapies, which include agents in development and thos e newly introduced for use in the clinic, include both traditional compound s and a growing number of biologic response modifiers. This article places these novel therapies within a pathophysiologic framework, highlighting com pletely new targets and therapeutic modalities.